Nothing spices up a patent dispute like a little name-calling. So we were eager to read Amgen's filing today in its patent case against Roche, after we got a juicy tip from Dow Jones Newswires' Thomas Gryta about it.
"With all the sincerity of a snake-oil salesman, Roche hyped its infringing product as a purportedly 'new' medicine conferring a different medical benefit," Amgen says in the document. "But Roche's own documents show that... its infringing product delivers at best 'non-inferior' or 'comparable' results."
Discuss Add this link to... Bury
"With all the sincerity of a snake-oil salesman, Roche hyped its infringing product as a purportedly 'new' medicine conferring a different medical benefit," Amgen says in the document. "But Roche's own documents show that... its infringing product delivers at best 'non-inferior' or 'comparable' results."
Discuss Add this link to... Bury
Comments